Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-803 + haNK + Avelumab in MCC
NCT03853317Phase 2Terminated
- Sponsor
- ImmunityBio, Inc.
- Start
- Feb 2020
- Primary completion
- Sep 2021
- Modality
- Cytokines & Interferons, Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of nogapendekin alfa inbakicept, haNK in Merkel cell carcinoma (MCC), sponsored by ImmunityBio, Inc.. Started Feb 2020; status: terminated.
02
Drugs
nogapendekin alfa inbakicepthaNK
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT03853317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03853317.